Psychosocial assessment and monitoring in the new era of non-interferon-alpha hepatitis C virus treatments

World Journal of Hepatology

Volumn 7, Issue 19, 2015, Pages 2209-2213

  Rowan, Paul J ^a   Bhulani, Nizar ^a  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Clinical; Depression; Direct acting antivirals; Psychiatry; Therapy

Indexed keywords

EID: 84941062611     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v7.i19.2209     Document Type: Short Survey

References (24)

1. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and causespecific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 385: 117-171 [PMID: 25530442 DOI: 10.1016/S0140-6736(14)616 82-2].
2. Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006; 130: 231-264; quiz 214-217 [PMID: 16401486 DOI: 10.1053/j.gastro.2005.11.010].
3. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-264 [PMID: 21371579 DOI: 10.1016/j. jhep.2011.02.023].
4. Talal AH, LaFleur J, Hoop R, Pandya P, Martin P, Jacobson I, Han J, Korner EJ. Absolute and relative contraindications to pegylatedinterferon or ribavirin in the US general patient population with chronic hepatitis C: results from a US database of over 45 000 HCV-infected, evaluated patients. Aliment Pharmacol Ther 2013; 37: 473-481 [PMID: 23289640 DOI: 10.1111/apt.12200].
5. Rowan PJ, Tabasi S, Abdul-Latif M, Kunik ME, El-Serag HB. Psychosocial factors are the most common contraindications for antiviral therapy at initial evaluation in veterans with chronic hepatitis C. J Clin Gastroenterol 2004; 38: 530-534 [PMID: 15220690 DOI: 10.1097/01.mcg.0000123203.36471.70].
6. Bhattacharya R, Shuhart MC. Hepatitis C and alcohol: interactions, outcomes, and implications. J Clin Gastroenterol 2003; 36: 242-252 [PMID: 12590237].
7. Bruggmann P, Dampz M, Gerlach T, Kravecz L, Falcato L. Treatment outcome in relation to alcohol consumption during hepatitis C therapy: an analysis of the Swiss Hepatitis C Cohort Study. Drug Alcohol Depend 2010; 110: 167-171 [PMID: 20334985 DOI: 10.1016/j.drugalcdep.2010.02.016].
8. Aspinall EJ, Corson S, Doyle JS, Grebely J, Hutchinson SJ, Dore GJ, Goldberg DJ, Hellard ME. Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin Infect Dis 2013; 57 Suppl 2: S80-S89 [PMID: 23884071 DOI: 10.1093/cid/cit306].
9. Micallef JM, Macdonald V, Jauncey M, Amin J, Rawlinson W, van Beek I, Kaldor JM, White PA, Dore GJ. High incidence of hepatitis C virus reinfection within a cohort of injecting drug users. J Viral Hepat 2007; 14: 413-418 [PMID: 17501762 DOI: 10.1111/ j.1365-2893.2006.00812.x].
10. Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 2006; 355: 2444-2451 [PMID: 17151366 DOI: 10.1056/NEJMct061675].
11. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski JP, Agarwal K, Buggisch P, Foster GR, Bräu N, Buti M, Jacobson IM, Subramanian GM, Ding X, Mo H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Mangia A, Marcellin P. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370: 1889-1898 [PMID: 24725239 DOI: 10.1056/NEJMoa1402454].
12. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982 [PMID: 12324553 DOI: 10.1056/NEJMoa020047].
13. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965 [PMID: 11583749 DOI: 10.1016/S0140-6736(01)06102-5].
14. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, Dienstag J, Lee WM, Mak C, Garaud JJ, Albrecht JK. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061-1069 [PMID: 12360468 DOI: 10.1053/ gast.2002.35950].
15. Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, Shiffman ML, Schiff E, Ghalib R, Ryan M, Rustgi V, Chojkier M, Herring R, Di Bisceglie AM, Pockros PJ, Subramanian GM, An D, Svarovskaia E, Hyland RH, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Pound D, Fried MW. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370: 1879-1888 [PMID: 24720702 DOI: 10.1056/NEJMoa1402355].
16. Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, Tam E, Marinho RT, Tsai N, Nyberg A, Box TD, Younes Z, Enayati P, Green S, Baruch Y, Bhandari BR, Caruntu FA, Sepe T, Chulanov V, Janczewska E, Rizzardini G, Gervain J, Planas R, Moreno C, Hassanein T, Xie W, King M, Podsadecki T, Reddy KR. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014; 370: 1983-1992 [PMID: 24795200 DOI: 10.1056/NEJMoa1402338].
17. Zeldin RK, Petruschke RA. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIVinfected patients. J Antimicrob Chemother 2004; 53: 4-9 [PMID: 14657084 DOI: 10.1093/jac/dkh029].
18. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. [Accessed 2015 Jun 15]. Available from: URL: http://www. aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL. pdf.
19. University of California at San Francisco HIV/AIDS Division. HIVInsite Gateway. [Accessed 2015 Jun 15]. Available from: URL: http://hivinsite.ucsf.edu/InSite.
20. El-Ibiary SY, Cocohoba JM. Effects of HIV antiretrovirals on the pharmacokinetics of hormonal contraceptives. Eur J Contracept Reprod Health Care 2008; 13: 123-132 [PMID: 18465473].
21. Ouellet D, Hsu A, Qian J, Locke CS, Eason CJ, Cavanaugh JH, Leonard JM, Granneman GR. Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. Br J Clin Pharmacol 1998; 46: 111-116 [PMID: 9723818].
22. Hafner V, Jäger M, Matthée AK, Ding R, Burhenne J, Haefeli WE, Mikus G. Effect of simultaneous induction and inhibition of CYP3A by St John's Wort and ritonavir on CYP3A activity. Clin Pharmacol Ther 2010; 87: 191-196 [PMID: 19924124 DOI: 10.1038/clpt.2009.206].
23. Smith KM, Romanelli F. Recreational use and misuse of phosphodiesterase 5 inhibitors. J Am Pharm Assoc (2003) 2005; 45: 63-72; quiz 73-75 [PMID: 15730119 DOI: 10.1331/1544345052843165].
24. Apodaca TR, Moser NC. The use and abuse of prescription medication to facilitate or enhance sexual behavior among adolescents. Clin Pharmacol Ther 2011; 89: 22-24 [PMID: 21170066 DOI: 10.1038/clpt.2010.264].